MASH
Banner
Why This Genotype Matters

The Three Most Clinically Relevant Liver Disease Loci

Genome-wide association studies have reproducibly mapped three loci as the strongest common genetic determinants of NAFLD/MASLD severity, MASH progression, liver fibrosis, and hepatocellular carcinoma risk. Each acts through a distinct biological mechanism in hepatocytes and stellate cells.

PNPLA3

I148M · rs738409 / rs738408

The strongest common genetic determinant of NAFLD severity. The G allele impairs the enzyme's lipase activity, leading to accumulation of triglycerides and retinyl esters in hepatocytes and stellate cells. Associated with steatosis, MASH progression, accelerated fibrosis, and elevated HCC risk across multiple ancestral populations.

Steatosis Fibrosis HCC Risk Stellate Cell Activation
TM6SF2

E167K · rs58542926

The T allele destabilizes TM6SF2, reducing hepatic VLDL secretion and increasing intracellular lipid retention. Associated with elevated steatohepatitis and fibrosis risk despite paradoxically reduced circulating LDL — reflecting impaired VLDL export, with implications for liver–cardiovascular crosstalk.

VLDL Secretion Steatohepatitis Lipid Trafficking
HSD17B13

TA-Indel Splice Variant · rs72613567

A protective loss-of-function variant. The TA insertion generates a truncated transcript, eliminating HSD17B13 activity. Associated with reduced MASH progression, cirrhosis risk, and protection against chronic liver disease. Particularly relevant for target validation, as HSD17B13 inhibition is under active clinical investigation.

Protective Allele Reduced MASH Risk Therapeutic Target
Available Genotypes

Genotype-Confirmed Primary Human Liver Cells

Cell Type Catalog No. PNPLA3 rs738409 TM6SF2 rs58542926 HSD17B13 rs72613567
Human Hepatocytes Key metabolic functions retained Cat. #5200 CC (WT) CG (Het) GG (Risk) Available Available
Human Hepatic Stellate Cells Incl. homozygous PNPLA3 risk lots Cat. #5300 CC (WT) CG (Het) GG (Risk) Available Available
Genotype is confirmed at all three loci. Each lot ships with a Certificate of Analysis (COA) confirming allele status. Contact info@sciencellonline.com for current lot availability by specific genotype combination.
Why Genotype-Defined Primary Liver Cells

Study Risk and Protective Backgrounds in the Same Primary Cell System

Standard hepatocyte and stellate cell lots are sourced from donors of unknown genotype. When PNPLA3, TM6SF2, and HSD17B13 status is uncontrolled, allele-driven differences in lipid handling, fibrogenic activation, and drug response contribute to variability that cannot be attributed to experimental conditions.

Study genotype–phenotype relationships directly

Link lipid accumulation, VLDL secretion, fibrogenic activation, or drug response to the allele status of each donor lot.

Compare risk and protective backgrounds

Run PNPLA3 risk-allele and wild-type hepatocytes side-by-side, or compare HSD17B13 loss-of-function donors against wild-type in the same assay.

Access the full allelic spectrum

Wild-type, heterozygous, and homozygous lots available for dose-response modeling across the complete genetic range.

Retain primary human liver biology

Native hepatocyte morphology, metabolism, CYP enzyme activity, and gene expression retained — no forced overexpression, no mutation artifacts.

Support pharmacogenomic drug development

Identify genotype-specific efficacy, safety, or toxicity signals in primary human cells before advancing to the clinic.

Target validation in relevant genetic backgrounds

HSD17B13 inhibitor studies are most meaningful in cells that carry the protective variant — now possible in primary human hepatocytes.

Research Applications

Applications Specific to Liver Genotype Biology

NAFLD/MASLD and MASH disease mechanism studies in genotype-stratified hepatocytes
Hepatic lipid accumulation and steatosis modeling by PNPLA3 allele status
VLDL assembly and secretion studies under TM6SF2 genotype backgrounds
HSD17B13 target validation and inhibitor response studies
Stellate cell activation and fibrogenesis in PNPLA3 homozygous risk backgrounds
Genotype-stratified hepatotoxicity and safety pharmacology screening
Lipid metabolism and lipid droplet biology
Transcriptomic and proteomic profiling by allele status
Co-culture and organoid models with genotype-matched cell types
Precision medicine and biomarker discovery in liver disease
Complete Liver Research Support

Available Cell Types

Human Hepatocytes — Cat. #5200

Genotyped for PNPLA3 (rs738409 & rs738408), TM6SF2 (rs58542926), and HSD17B13 (rs72613567). Key metabolic functions retained.

View product →

Human Hepatic Stellate Cells — Cat. #5300

Genotyped across all three loci. Select lots include homozygous PNPLA3 risk-allele backgrounds critical for fibrosis mechanism studies.

View product →
How to Order

Requesting Genotype-Defined Liver Cell Lots

Genotype-defined lots are available by request. Lot availability varies by genotype. A selection and verification fee applies per vial.

1

Identify the Cell Type

Identify the cell type — hepatocytes (Cat. #5200) or hepatic stellate cells (Cat. #5300)

2

Specify Liver Cell Genotype

Specify the locus/loci and allele status required — single or multi-locus genotype combinations available

3

Submit Your Request

Our team will confirm available lots and provide a quote with COA documentation for all genotyped loci.

Need Help With Genotype Selection?

Please note that availability varies by genotype and donor lot. A selection and verification fee will be applied per vial and reflected in your quote.

For information on available genotypes, assistance selecting the right cells, or inquiries about additional genotypes and cell types, please contact us at info@sciencellonline.com, or call 1.877.602.8549.